Authors
Latest:
Prospective Data Establishing the Clinical Utility of Testing All Biomarkers in Advanced Bladder Cancer is Still Needed, Says ExpertWith the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.
Latest:
CANCER TREATMENT CENTERS OF AMERICA RECEIVES 2021 PRESS GANEY GUARDIAN OF EXCELLENCE AWARD®Comprehensive cancer centers in Chicago and Atlanta earn national distinction as top performers in patient experience.
Latest:
Clinical Trials in Progress: ROADS TrialPhase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS; NCT04365374)
Latest:
A 65-Year-Old Man With Back Pain and Imaging Findings of Spinal Cord CompressionMehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.
Latest:
Combatting Stigmatization to Increase Lung Cancer Screening AccessLisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
Latest:
Multiple Myeloma: Unmet Needs and Future PerspectivesClosing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.
Latest:
Closing Thoughts: Key Messages for Clinicians and Patients in the Treatment of HER2+ Breast CancerPanelists discuss advice for nurses collaborating with oncologists in treating patients with HER2+ breast cancer, as well as closing messages for patients receiving treatment and clinicians involved in the care of those with advanced HER2+ breast cancer.
Latest:
Future Perspectives and Unmet Needs in Multiple MyelomaThe expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Latest:
Luveltamab Tazevibulin Elicits Response in Platinum-Resistant Ovarian Cancer, Low/Medium FRα ExpressionThe REFRαME-O1 trial improved response in patients with FRα–positive platinum-resistant ovarian cancer, including those with low to medium expression when given luveltamab tazevibulin.
Latest:
Expert Insight and Future Perspectives for Follicular LymphomaPanelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
Latest:
Catherin Watson, MD, Assesses the Future of Genetic Testing in Ovarian CancerAt SGO 2022, Catherine Watson, MD, spoke about how to encourage patients with ovarian cancer to seek genetic testing.
Latest:
A Rare Case of Glioblastoma With Extensive Liver MetastasesGhulam Gous, MD, and colleagues report a case of glioblastoma with extensive liver metastases along with a review of previous reports of liver metastasis from glioblastomas and the possible mechanisms of metastasis.
Latest:
Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in CareBest treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
Latest:
Data Show Underutilization of Appendectomy in Appendix Cancer PopulationA lack of guidelines, a loss of follow-up, and out-of-state procedures are all potential reasons for 26% of patients undergoing appendectomy.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
Future Perspectives: Treating Multiple Myeloma With Novel RegimensAn overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.
Latest:
KRAS+ NSCLC: Treatment Management StrategiesThis video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.
Latest:
Exploring the Future of ctDNA and Novel Treatment StrategiesPanelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.
